Cargando…
OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer
c-MET is considered a driver of cancer progression, impacting tumor growth and tumor-supporting stroma. Here, we investigated the therapeutic efficacy of OMO-1, a potent and selective c-MET inhibitor, in an immunocompetent intraductal mouse model for triple-negative breast cancer (TNBC). OMO-1 reduc...
Autores principales: | Steenbrugge, Jonas, Vander Elst, Niels, Demeyere, Kristel, De Wever, Olivier, Sanders, Niek N., Van Den Broeck, Wim, Ciamporcero, Eric, Perera, Timothy, Meyer, Evelyne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969607/ https://www.ncbi.nlm.nih.gov/pubmed/33731699 http://dx.doi.org/10.1038/s41523-021-00234-8 |
Ejemplares similares
-
One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer
por: Steenbrugge, Jonas, et al.
Publicado: (2022) -
Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer
por: Steenbrugge, Jonas, et al.
Publicado: (2019) -
Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer
por: Steenbrugge, Jonas, et al.
Publicado: (2018) -
Xenogeneic equine stem cells activate anti-tumor adaptive immunity in a 4T1-based intraductal mouse model for triple-negative breast cancer: proof-of-principle
por: Steenbrugge, Jonas, et al.
Publicado: (2023) -
Non-Classical ProIL-1beta Activation during Mammary Gland Infection Is Pathogen-Dependent but Caspase-1 Independent
por: Breyne, Koen, et al.
Publicado: (2014)